Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resveratrol in Schizophrenia
NCT02062190Phase 2Completed
- Sponsor
- Universidade Federal do Rio Grande do Sul
- Start
- Mar 2014
- Primary completion
- Jan 2015
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia (2 arms), sponsored by Universidade Federal do Rio Grande do Sul. Primary endpoint: Cardiovascular risk markers (Cytokines, C-reactive protein, Cholesterol) at 1 month. Started Mar 2014; status: completed.
02
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02062190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02062190.